Related Experiment Videos
Selective estrogen-receptor modulators in 2001
1Division of Hematology and Medical Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.
Oncology (Williston Park, N.Y.)
|October 9, 2001
Summary
Selective estrogen-receptor modulators (SERMs) like tamoxifen treat breast cancer but have side effects. Research is exploring new agents to improve efficacy and safety, aiming to reduce adverse events while maintaining benefits.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Tamoxifen is the primary endocrine therapy for hormone-responsive breast cancer and is FDA-approved for breast cancer risk reduction.
- Tamoxifen exhibits both antiestrogenic effects in breast tissue and paradoxical estrogenic effects in other tissues, impacting bone mineral density and increasing endometrial cancer risk.
- Adverse effects of tamoxifen include hot flashes and thromboembolic events, driving research into safer alternatives.
Purpose of the Study:
- To review current research on novel agents for breast cancer endocrine therapy.
- To compare the efficacy and safety profiles of existing and emerging treatments.
- To identify agents that maintain tamoxifen's benefits while mitigating its adverse effects.
Main Methods:
- Review of current research and clinical trials on selective estrogen-receptor modulators (SERMs) and aromatase inhibitors.
- Comparison of tamoxifen's established effects with those of raloxifene and other developing SERMs.
- Examination of agents in preclinical and clinical development for breast cancer treatment and prevention.
Main Results:
- Raloxifene, another SERM, is approved for osteoporosis prevention and is being compared to tamoxifen in breast cancer prevention.
- Raloxifene shares side effects with tamoxifen, such as hot flashes and thromboembolic events; its effect on endometrial cancer risk is under investigation.
- New SERMs and selective aromatase inhibitors are under development to improve upon tamoxifen's safety profile in early breast cancer settings.
Conclusions:
- Ongoing research aims to develop safer and more effective endocrine therapies for breast cancer.
- New SERMs and aromatase inhibitors show promise in improving treatment outcomes and reducing adverse events.
- The development of novel agents seeks to balance the therapeutic benefits of estrogen modulation with an improved safety profile.